The Potential of Rosuvastatin and Candesartan [candesartan cilexetil] to Retard the Progression of Aortic Stenosis Influences of Medical Therapy to the Atheroinflammatory Process in Stenotic Aortic Valves.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Aortic valve stenosis
- Focus Pharmacodynamics
- Acronyms ROCK-AS
- 20 May 2009 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 12 Jul 2008 New trial record.